EDIT Editas Medicine, Inc.
Price Chart
Executive Summary
Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92 loss in Q1 2025, driven by significant cost reductions from the discontinued reni-cel program. Collaboration revenue fell to $2.8M from $4.7M, and cash burn continued with cash dropping to $123.6M from $146.6M at year-end 2025. The PTAB reaffirmed the Broad Institute's CRISPR-Cas9 patent position, a neutral legal development for the company's licensed IP.
Actionable Insight
The quarter was a non-event operationally — the narrower loss was entirely cost-driven, not revenue growth. The stock will trade on EDIT-401 clinical catalysts: IND/CTA submission by mid-2026 and first human proof-of-concept data by year-end 2026. Monitor for any delays in these milestones or additional financing needs given the $123.6M cash balance.
Key Facts
- Net loss per share improved to -$0.26 from -$0.92 YoY, driven by a 66% reduction in operating expenses
- Collaboration revenue declined 39% YoY to $2.8M as prior-year partner milestones concluded
- Cash and equivalents fell to $123.6M, down from $146.6M at Dec 2025; runway guided into Q3 2027
- EDIT-401 IND/CTA submission on track for mid-2026 with first-in-human trial initiation expected later this year
- PTAB reaffirmed Broad Institute's CRISPR-Cas9 patent position for the third time; CVC retains appeal rights
- No restructuring charges in Q1 2026 vs $40.9M in Q1 2025, reflecting completion of reni-cel wind-down
Financial Impact
Net loss improved by $51.1M YoY to -$25.0M; cash burn of $23.0M in Q1 2026
Risk Factors
- Cash runway only into Q3 2027; may require dilutive financing before EDIT-401 data readout
- EDIT-401 is still preclinical; clinical failure or regulatory delays would reset the investment thesis
- CVC may appeal PTAB decision, creating long-term patent uncertainty for the licensed Cas9 IP
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001650664-26-000043 |
| Document: edit-20260505.htm | 0001650664-26-000043 |
| Document: 0001650664-26-000043-index-headers.html | 0001650664-26-000043 |
| Document: 0001650664-26-000043-index.html | 0001650664-26-000043 |
| Document: 0001650664-26-000043.txt | 0001650664-26-000043 |
| 8-K Data (Synthetic) | 0001650664-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.49 awaiting T+5 | awaiting T+5 | — | $2.50 (+0.60%) |
|
May 26, 2026
19d ago
|
424B5
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
19d ago
|
8-K
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
19d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
19d ago
|
8-K
| $3.08 $3.34 | ▲ +8.44% | ▲ +7.36% | $2.50 (−18.83%) |
|
May 26, 2026
19d ago
|
424B5
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
19d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
19d ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −9.65% | $2.50 (−18.83%) |
|
May 14, 2026
4w ago
|
8-K
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
|
May 14, 2026
4w ago
|
Press Release
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access